In esophageal adenocarcinoma cases, the proportion of DSG3 immunoreactive cells was much lower and showed no significant difference between MD and PD cases (mean, 2% vs. 2%, respectively; p > 0.05) (Table 4). This evidence concerns the gene DSG3 and esophageal adenocarcinoma.